NR3C2 and hydrops fetalis: In this review, we aim to provide an overview of the pathophysiological rationale for mineralocorticoid receptor antagonism in HFpEF and HFmrEF, integrating evidence from the recent FINEARTS-HF trial within the broader context of HF management.